ClinicalTrials.gov

History of Changes for Study: NCT00572130
Phase II Study of Intravenous Rexin-G in Osteosarcoma
Latest version (submitted June 9, 2011) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 December 11, 2007 None (earliest Version on record)
2 October 5, 2008 Recruitment Status, Study Status and Contacts/Locations
3 February 4, 2010 Study Status
4 June 9, 2011 Recruitment Status, Study Status and Study Design
Comparison Format:

Scroll up to access the controls

Study NCT00572130
Submitted Date:  December 11, 2007 (v1)

Open or close this module Study Identification
Unique Protocol ID: C07-110
Brief Title: Phase II Study of Intravenous Rexin-G in Osteosarcoma
Official Title: A Phase II Study of Intravenous Rexin-G in Recurrent or Metastatic Osteosarcoma
Secondary IDs:
Open or close this module Study Status
Record Verification: December 2007
Overall Status: Recruiting
Study Start: December 2007
Primary Completion:
Study Completion: December 2008 [Anticipated]
First Submitted: December 10, 2007
First Submitted that
Met QC Criteria:
December 11, 2007
First Posted: December 12, 2007 [Estimate]
Last Update Submitted that
Met QC Criteria:
December 11, 2007
Last Update Posted: December 12, 2007 [Estimate]
Open or close this module Sponsor/Collaborators
Sponsor: Epeius Biotechnologies
Responsible Party:
Collaborators:
Open or close this module Oversight
U.S. FDA-regulated Drug:
U.S. FDA-regulated Device:
Data Monitoring: Yes
Open or close this module Study Description
Brief Summary: Rexin-G is a tumor-targeted gene medicine that is designed to seek out and destroy both primary tumors and metastatic cancers without the side effects of standard chemotherapy. The objectives of the study are: (1) to evaluate the clinical effectiveness of intravenous injections of Rexin-G, a tumor-targeted gene vector, in controlling tumor growth and prolonging life, and (2) to evaluate its over-all safety.
Detailed Description:

The adaptive trial design of this advanced Phase II study incorporates (i) a dosing schedule based on the patient's estimated tumor burden and not on standard dosing per kilogram body weight or body surface area, and (2) a tumor response evaluation process that is unique to the manner in which osteosarcoma responds favorably to therapy, i.e., with necrosis and increasing calcification in metastatic tumors and decreased glucose utilization using PET-CT imaging studies.

Twenty to thirty patients will receive Rexin-G at either Dose Level 1 or 2. Patients will be assigned a dose level based on the estimated tumor burden as measured by PET-CT imaging studies. Estimated tumor burden is measured by multiplying the sum of the longest diameters of target lesions in cm by 10e9 cancer cells. If the tumor burden is less than 10 billion cells, the patient will be assigned to Dose Level 1, if the tumor burden is greater than 10 billion cells, the patient will be assigned to Dose Level 2.

*Treatment Cycle Dose Level Vector Dose/Day Max.Volume/Dose

Two times a week 1 1.0 x 10e11 cfu 200 ml

Three times a week 2 1.0 x 10e11 cfu 200 ml

* Each treatment cycle will be six weeks (four weeks of treatment and two weeks of rest). Patients who have resolution of toxicity to < grade I may have repeat cycles. After one or more treatment cycles, the principal investigator may recommend surgical debulking or complete surgical removal. If residual disease is present either by histopathological examination or by PET-CT scan, repeat treatment cycles may be given 3-4 weeks after surgery, if the surgical incision has healed, and if the patient has < grade I toxicity.

Open or close this module Conditions
Conditions: Osteosarcoma
Keywords: Tumor-targeted gene medicine
Cyclin G1 gene
Osteosarcoma
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Treatment
Study Phase: Phase 2
Interventional Study Model: Parallel Assignment
Number of Arms: 2
Masking: None (Open Label)
Allocation: Non-Randomized
Enrollment: 30 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Experimental: Rexin-G Dose 1 Genetic: Rexin-G Dose 1
Rexin-G i.v., 1 x 10e11 cfu, two times a week x 4 weeks, rest 2 weeks May be repeated if grade 1 or less toxicity
Experimental: Rexin-G Dose 2 Genetic: Rexin-G Dose 2
Rexin-G i.v., 1 x 10e11 cfu, three times a week x 4 weeks; rest 2 weeks May repeated if grade 1 or less toxicity
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Clinical efficacy as measured by over-all response rates (either CR, PR or SD) by International PET criteria
[ Time Frame: 12-18 months ]

Secondary Outcome Measures:
1. Clinical efficacy as measured by progression-free survival greater than one month and over-all survival of 6 months or longer; clinical toxicity measures
[ Time Frame: 12-18 months ]

Open or close this module Eligibility
Minimum Age: 10 Years
Maximum Age:
Sex: All
Gender Based:
Accepts Healthy Volunteers: No
Criteria:

Inclusion Criteria:

  1. Patient with recurrent or metastatic osteosarcoma who is considered refractory to known therapies.
  2. Histologically or cytologically confirmed osteosarcoma that is measurable.
  3. Adequate hepatic function: Total bilirubin < 2.0 mg/dL (upper limit included); AST/ALT < 2x institutional norm; alkaline phosphatase < 2.5x upper limit of institutional norm unless the patient has extensive bone metastases. Patients with elevated alkaline phosphatase due to extensive liver disease will be excluded from study; albumin > 3.0 mg/dL. There must be no substantial ascites. PT and PTT must be within normal limits.
  4. Performance status must be < 1 (ECOG 0-1) with a life expectancy of at least 3 months.
  5. Hemoglobin > 9 gms%
  6. Absolute granulocyte count > 1000/uL, and platelet count > 100,000/uL.
  7. Serum creatinine of less than 1.5 mg%.
  8. There must be no plans for the patient to receive further cancer therapy from the date of enrollment until the completion of the 6-week follow-up visit.
  9. Accessibility of peripheral or central IV line
  10. Age > 10 years
  11. Patients will be off chemotherapy for a minimum of 4 weeks prior to initiation of therapy and should have recovered to Grade 1 or less toxicity.
  12. The ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  1. Prior malignancy, except for non-melanoma skin cancer, stage 1 breast cancer, CIS of cervix from which the patient has been disease-free for 5 years.
  2. Woman who are pregnant or nursing
  3. Fertile patients unless they agree to use barrier contraception (condoms and spermicide jelly) during the vector infusion period and for six weeks after infusion. Male patients must agree to use barrier contraception.
  4. Patients who are transfusion dependent (more than one transfusion per month)
  5. Patients with medical, psychiatric, or social conditions that would compromise successful adherence to this protocol.
  6. Patient who do not meet the inclusion criteria.
Open or close this module Contacts/Locations
Central Contact Person: Erlinda M Gordon, M.D.
Telephone: 626-441-6695
Email: egordon@epeiusbiotech.com
Central Contact Backup: Frederick L. Hall, Ph.D.
Telephone: 626-441-6695
Email: fhall@epeiusbiotech.com
Study Officials: Sant P Chawla, M.D.
Principal Investigator
Epeius Clinical Research Unit/Sarcoma Oncology Center
Locations: United States, California
Epeius Clinical Research Unit/Sarcoma Oncology Center
[Recruiting]
Los Angeles, California, United States, 91108
Contact:Principal Investigator: Sant P Chawla, M.D.
Open or close this module IPDSharing
Plan to Share IPD:
Open or close this module References
Citations:
Links:
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services